Sign in Subscribe

Topic

VIP

A collection of 20 issues

SLC22A1 VIP Summary Published in PG&G

Solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also called OCT1) is an important drug transporter mediating the hepatic uptake of many commonly used drugs. Several SLC22A1 variants have functional consequences and have been associated with altered disposition and response for drugs such as metformin, imatinib, sorafenib, tropisetron,

New PharmGKB VIP Summary: SLC22A1 (OCT1)

Solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also called OCT1) is a polyspecific cationic transporter mediating the uptake of many organic cations from the blood into epithelial cells. It is predominantly expressed in the liver and plays a critical role in the hepatic uptake of many commonly

New EGFR VIP Summary Published in PG&G

The epidermal growth factor receptor (EGFR) is involved in the growth of many epithelial malignancies, such as non-small-cell lung cancer (NSCLC), pancreatic and colorectal cancer. It has therefore been a key target for the development of cancer therapeutics. These include tyrosine kinase inhibitors (gefinitib and erolinitib) and monoclonal antibodies (cetuximab

CYP2C8 VIP published in PG&G

CYP2C8 is a member of the cytochrome P450 family of drug metabolizing enzymes. It plays a major role in the metabolism of many commonly used drugs. Several CYP2C8 SNPs have been associated with variability in metabolism, disposition and response for drugs such as repaglinide, rosiglitazone, pioglitazone, paclitaxel, bisphosphonates, amiodarone and

New PharmGKB VIP Summary: NAT2

N-acetyltransferase enzymes (NAT1 and NAT2) are involved in the metabolism and detoxification of xenobiotics. NAT2 is predominantly expressed in the liver and has a role in the metabolism of numerous therapeutic drugs including caffeine and BiDil. Genetic variants in the NAT2 gene result in a slow, intermediate or rapid acetylator

New VIP Summary for CYP2C8

A new VIP summary is available for CYP2C8, a member of the cytochrome P450 family of drug metabolizing enzymes. CYP2C8 accounts for 7% of CYP content in the liver, and is expressed to a lesser extent in the kidney, adrenal gland, mammary gland, brain, ovary, uterus, and duodenum. CYP2C8 plays

Updated UGT1A1 VIP Summary

We have updated the UGT1A1 VIP summary to provide more in-depth information on this important pharmacogene. UGT1A1 is a member of the uridine diphosphate glucuronosyltransferase (UGT) enzyme family, and is responsible for the glucuronidation of target substrates. The transfer of glucuronic acid renders xenobiotics and other endogenous compounds water soluble,

New VIP gene summary for CYP2E1

A new VIP summary is available for CYP2E1, a member of the cytochrome P450 family of drug metabolizing enzymes. CYP2E1 is constitutively expressed in the liver but makes up less than 1% of the total hepatic P450 isoforms [Article: 20100563]. It metabolizes relatively few prescription drugs (approximately 2%), however its

Vitamin D receptor (VDR) polymorphisms and treatment responses

The human VDR protein is trans-acting transcriptional factor. It binds the active form of vitamin D (1,25-dihydroxyvitamin D3) to modulate many biological activities of the neural, immune and endocrine systems. Poon et al. have recently written an updated Very Important Pharmacogene (VIP) Summary for VDR gene that is published

How might genetic variants of a single gene affect addiction to cigarettes and response to anti-cancer therapy?

The human CYP2A6 enzyme is involved in the metabolism of many different compounds - including those found in our diet and therapeutic drugs. We have recently written an updated Very Important Pharmacogene (VIP) Summary that is published in Pharmacogenetics and Genomics. CYP2A6 has a major role in the metabolism of